Welcome to our dedicated page for Bayview Acquisition SEC filings (Ticker: BAYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bayview Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bayview Acquisition's regulatory disclosures and financial reporting.
Bayview Acquisition Corp reported that on August 14, 2026 it deposited $50,000 into its trust account to obtain a one-month extension of the deadline to complete its initial business combination. This extends the deadline from August 19, 2026 to September 19, 2026.
The company states this is the third of up to six extensions allowed under its Second Amended and Restated Articles of Association, as amended. The units, ordinary shares, and rights of Bayview Acquisition Corp continue to trade on The Nasdaq Stock Market LLC under the symbols BAYAU, BAYA, and BAYAR, respectively.
Bayview Acquisition Corp, a Cayman Islands SPAC, reported a net loss of $743,135 for the six months ended June 30, 2026, driven by $949,825 of formation and operating costs, partially offset by $206,690 of interest and dividend income on trust and bank balances.
Total assets were $10.9 million, including $10.8 million held in a trust account and minimal cash of $50,543, against $6.9 million of liabilities and a working capital deficit of $4.66 million. After multiple shareholder redemptions, 881,636 ordinary shares remain subject to possible redemption at $12.21 per share, with 1,732,500 non-redeemable shares outstanding.
The company continues to pursue a business combination with Oabay under an amended merger agreement featuring revenue-based earnout thresholds (up to 6,000,000 earnout shares). Management discloses substantial doubt about its ability to continue as a going concern if no merger is completed by the extended deadline of December 19, 2026, and also highlights a Nasdaq determination to delist its securities, which the company is appealing.
Bayview Acquisition Corp deposited $50,000 into its trust account on July 14, 2026 to extend the period it has to consummate its initial business combination by one month, moving the deadline from July 19, 2026 to August 19, 2026. This Extension is described as the second of up to six extensions permitted under the Company’s Second Amended and Restated Articles of Association, as amended.
Bayview Acquisition Corp reports that a Nasdaq Hearings Panel has decided to delist its securities after the company failed to complete its business combination with Oabay, Inc. by June 19, 2026, a condition for continued listing.
Nasdaq will suspend trading of Bayview’s units, ordinary shares and rights on July 7, 2026, and a Form 25-NSE will remove them from Nasdaq listing and registration. Bayview plans to ask the Nasdaq Listing and Hearing Review Council to review the delisting decision within the allowed 15-day window, but there is no assurance this review will change the outcome.
Bayview Acquisition Corp deposited $50,000 into its trust account to buy more time to complete its first acquisition. This payment extends the deadline to consummate its initial business combination by one month, shifting it from June 19, 2026 to July 19, 2026.
The company describes this as the first of up to six possible one-month extensions allowed under its current Second Amended and Restated Articles of Association. The payment creates a direct financial obligation tied to maintaining the SPAC’s opportunity to close a qualifying deal.
Bayview Acquisition Corp filed an amended report detailing shareholder approval to extend its deadline to complete an initial business combination. The company can now push its Termination Date from June 19, 2026 to December 19, 2026 through up to six one-month extensions, each requiring a $50,000 deposit into the Trust Account.
At the May 28, 2026 extraordinary general meeting, 2,291,094 ordinary shares, or about 83.67% of shares outstanding as of the record date, were represented, and both the charter amendment and trust agreement amendment passed unanimously. Ten holders redeemed 124,156 ordinary shares at approximately $12.11 per share, for total redemptions of about $1,503,642.93.
Bayview Acquisition Corp shareholders approved extending the deadline to complete its initial business combination from June 19, 2026 to as late as December 19, 2026, through up to six one‑month extensions, each requiring a $50,000 deposit into the trust account.
At the extraordinary general meeting, holders of 2,291,094 ordinary shares, about 83.67% of shares as of the May 4, 2026 record date, were represented, and both the charter amendment and trust agreement amendment passed unanimously.
Only 124,156 shares, representing less than 5% of total shares outstanding, were redeemed at approximately $12.03 per share, for about $1.49 million in total. The company highlighted that this low redemption level supports its efforts to complete a business combination with Oabay Inc.
Bayview Acquisition Corp, a blank-check company, reported a net loss of $367,344 for the three months ended March 31, 2026, driven by formation and operating costs of $471,513 partly offset by $104,169 of interest income, mainly from its trust account.
Total assets were $12,141,160, including $12,014,746 of investments in the trust account and cash of $50,187, against total liabilities of $6,262,168 and ordinary shares subject to possible redemption of $12,014,746, leaving a shareholders’ deficit of $6,135,754.
Management disclosed a working capital deficit of $4,035,754 and stated that these conditions, along with the need to complete a business combination by the required dates, raise substantial doubt about Bayview’s ability to continue as a going concern. The company is pursuing a merger with Oabay under a multi-step Merger Agreement and has repeatedly extended its combination deadline through shareholder-approved extensions funded by Oabay promissory notes totaling $1,925,000 deposited into the trust. Bayview also received a Nasdaq panel decision allowing continued listing subject to closing the Oabay business combination and meeting initial listing standards by June 19, 2026, while a later amendment to the Merger Agreement extended the outside closing date to December 19, 2026.
Bayview Acquisition Corp entered into Amendment No. 4 to its previously disclosed Merger Agreement, extending the Outside Closing Date. The parties agreed to extend the Outside Closing Date to December 19, 2026. The filing references prior amendments, including the original Merger Agreement dated June 7, 2024, Amendment No. 1 dated June 26, 2024, Amendment No. 2 dated May 14, 2025, and Amendment No. 3 dated January 21, 2026. A copy of Amendment No. 4 is filed as Exhibit 2.1 and is incorporated by reference.
Bayview Acquisition Corp has amended its merger agreement again, extending the deadline to close its planned business combination. On May 19, 2026, the parties signed Amendment No. 4, moving the Outside Closing Date to December 19, 2026 from the prior June 15, 2026.
This follows earlier amendments that revised earnout milestones based on new consolidated revenue metrics and realigned the transaction sequence. The report notes that forward-looking statements are subject to risks and uncertainties, and there is no assurance the company will achieve the expectations described.